ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 98

Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases

Christie Fanton1, Neha Dixit 1, Suresh Siddhanti 1, Lin Lu 1, Daniel Dickerson 2, Brian Kotzin 1 and Jonathan Zalevsky 1, 1Nektar Therapeutics, San Francisco, 2PRA Health Sciences, Lenexa

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: CTLA-4 and IDO1, demethylated FoxP3, first in human, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Regulatory T cell (Treg) dysfunction and impaired IL-2 production have been implicated as key immunological defects in multiple autoimmune diseases. Enhanced sensitivity of Tregs to IL-2 supports use of low-dose IL-2 therapy; however, this treatment is limited by short half-life and relatively poor selectivity for stimulation of Tregs versus other conventional T cell (Tcon) subsets and natural killer (NK) cells. NKTR-358 is a polyethylene glycol (PEG) conjugate of recombinant human IL‑2 (aldesleukin sequence with no additional amino acid mutation or substitution), and is being developed with the goal to selectively restore Treg numbers and function in autoimmune disease. NKTR-358 demonstrates prolonged biological activity as well as marked and selective stimulation of Tregs in different animal species as compared to native IL-2.

Methods: In this first-in-human, double-blind, single ascending dose study, healthy volunteers received subcutaneous doses of NKTR-358 ranging from 0.3 to 28.0 µg/kg (9 active: 3 placebo per cohort) and were followed for 50 days. The time course and extent of activation and proliferation of Tregs, Tcons, and NK cells were assessed. In addition, suppressive function of Tregs, as well as changes in gene expression and epigenetic markers in peripheral blood lymphocytes were investigated.

Results: All 8 planned cohorts completed dosing. There were no dose-limiting toxicities, serious adverse events, deaths, or clinically significant abnormalities in vital signs, electrocardiograms, or laboratory test values. The primary effect of NKTR‑358 was seen on Tregs. In the 3.0 to 28.0 µg/kg dose cohorts, dose-dependent and sustained increases in the absolute numbers, percentages, and proliferation (Ki67+) of circulating FoxP3+CD25bright Tregs were observed. At 28.0 µg/kg, the mean peak increase in numbers of CD25bright Tregs was 17-fold above baseline, and the mean percentage of Ki67+ CD25bright Tregs was 6-fold above baseline. No increases in numbers of CD4+ or CD8+ Tcons were detected and the number of NK cells was increased < 4-fold at the highest dose tested. In addition to increased Treg numbers, expression of Treg activation markers ICOS and CTLA-4 increased at doses >20 μg/kg. NKTR-358-induced Tregs maintained their suppressive capacity as shown by the ability to suppress CD4+ Tcon cell proliferation in an ex vivo assay. Induction of Treg numbers was further supported by epigenetic analysis of immune cells demonstrating an increase in demethylated FOXP3. Finally, NKTR-358 administration led to dose-dependent induction of genes associated with Treg regulation, such as IDO1 and CD38.

Conclusion: In continuation of results previously reported, single ascending doses of NKTR-358 led to a dose-dependent increase in proliferation of CD25bright Tregs. The induced Tregs displayed functional activity as evidenced by increased levels of activation markers and the capacity to suppress proliferation of Tcons. These clinical results extend previously reported effects of NKTR-358 on selective Treg stimulation and provide strong support for studying NKTR-358 as a new therapeutic in inflammatory and autoimmune diseases, such as systemic lupus.


Disclosure: C. Fanton, Nektar Therapeutics, 1, 3, 4; N. Dixit, Nektar Therapeutics, 1, 3, 4; S. Siddhanti, Nektar Therapeutics, 1, 3, 4; L. Lu, Nektar Therapeutics, 1, 3, 4; D. Dickerson, None; B. Kotzin, Nektar Therapeutics, 1, 3, 4; J. Zalevsky, Nektar Therapeutics, 1, 3, 4.

To cite this abstract in AMA style:

Fanton C, Dixit N, Siddhanti S, Lu L, Dickerson D, Kotzin B, Zalevsky J. Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/selective-induction-of-functional-regulatory-t-cells-in-healthy-volunteers-by-nktr-358-a-novel-il-2-conjugate-treg-stimulator-in-development-for-the-treatment-of-autoimmune-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/selective-induction-of-functional-regulatory-t-cells-in-healthy-volunteers-by-nktr-358-a-novel-il-2-conjugate-treg-stimulator-in-development-for-the-treatment-of-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology